Naloxone-HCI is the first pure narcotic antagonist to be discovered and it is used for the treatment of narcotic overdose and reversal of narcotic analgesia. Recently, the effect of Naloxone-HCI on the CNS lesion was approved by laboratory and clinical studies.
This study was intended to evaluate the clinical effect of Naloxone-HCI on the CNS lesion and was performed with 129 patients of the CNS lesion, who were admitted and managed at the Department of Neurosurgery of Chungnam National University Hospital from Mar. 1985 to Apr. 1987.
The results were as follows;
1. In the patients with spontaneous intracerebral hematoma, the percentage of improvement were 63% in Naloxone-HCI treated group 42% in control group. In the patients with brain contusion it were 64% in Naloxone-HCI treated group and 77% in control group. But, when excluding the patients below 7 points of GCS, the percentage of improvement were 70% in Naloxone-HCI treated group and 50% in control group of the patients with spontaneous intracerebral hematoma. In the patients with brain contusion, it were 100% in Naloxone-HCI treated group and 80% in control group.
2. In the patients with spinal cord injury, the improvement was noted in all cases with incomplete motor paralysis, but the cases with complete motor paralysis were not improved without significant relation to Naloxone-HCI.
3. There was no significant differentiation in the average time of improvement between Naloxone-HCI treated group and control group.
|